Skip to main content
Premium Trial:

Request an Annual Quote

KPL Licenses Expression Pathology s Protein-Extraction Tech for Use in Upcoming Products

NEW YORK, July 21 (GenomeWeb News) - As part of a license-and-supply agreement, Kirkegaard and Perry Laboratories (KPL) has gained exclusive rights to market protein immunodetection products based on Expression Pathology's Liquid Tissue technology in the life-science research market, the companies said today in a statement.

 

KPL will integrate Expression Pathology's technology, which enables protein extraction from formalin-fixed paraffin-embedded tissue samples, with its own immunodetection reagents, the companies said. The products will allow customers to create reverse-phase arrays and dot blots, and to characterize and validate protein biomarkers, the companies added.

 

KPL said it will launch protein-extraction and -detection products resulting from the partnership "later this year."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.